Try our Advanced Search for more refined results

Regeneron Pharmaceuticals, Inc. v. Amgen Inc.

  1. June 03, 2025

    Regeneron Gets $407M After Antitrust Win Over Amgen

    Regeneron won a $406.8 million judgment in its antitrust suit against Amgen, following a jury verdict last month saying Amgen illegally undercut the price of Regeneron's anticholesterol drug Praluent through a bundling scheme with two blockbuster Amgen drugs.

  2. May 15, 2025

    Regeneron Wins $271.2M In Amgen Antitrust Suit

    A federal jury in Delaware put Amgen Inc. on the hook Thursday for at least $271.2 million in punitive damages arising from an alleged scheme that undercut Regeneron's price for its Praluent anti-cholesterol drug by bundling Amgen's competing, higher-priced Repatha with rebates for two expensive, blockbuster medications. 

  3. May 14, 2025

    Regeneron-Amgen Trial Goes To Jury With An Extra Day

    Federal jurors started deliberating on a Regeneron Pharmaceuticals Inc. antitrust suit late Wednesday accusing Amgen Inc. of tripping up Regeneron's anti-cholesterol drug insurance eligibility by illegally bundling Amgen's competing version with rebates for two unrelated drugs, with potential triple damages in the balance.

  4. May 13, 2025

    Regeneron-Amgen Drug Bundling Trial Heads Toward Jury

    An economics expert called by Amgen Inc. told a Delaware federal jury Tuesday that none of the company's deals to bundle other discounted major medications with its cholesterol-reducing drug Repatha foreclosed market competition, a day before jurors begin deliberating on an antitrust suit targeting the practice.

  5. May 05, 2025

    Regeneron, Amgen Open Drug 'Bundling' Trial In Del.

    The founder and CEO of Regeneron Inc. told a federal jury in Delaware on Monday that a major pharmacy benefit insurer told him in mid-2020 his company was wasting its time in trying to keep a cholesterol-drug supply contract, with Amgen Inc. offering a better-priced but allegedly anticompetitive multidrug portfolio.

  6. April 11, 2025

    Amgen Can't Ditch Regeneron's Bundling Antitrust Suit

    A Delaware federal judge on Thursday denied Amgen's bid to toss antitrust litigation brought by Regeneron accusing its rival of using a bundling scheme to increase the sales of its cholesterol drug Repatha and push competitors out of the market.

  7. March 30, 2023

    Off Beat: Funding, Face-Offs & Food Fights

    A Texas federal judge who does significant patent work will be stepping down, drug companies sparring over patents at the U.S. Supreme Court found themselves again going toe-to-toe over a different area of law, California judges provided trial tips throughout March, and the integrity of popular snacks was brought into question in Illinois. Here's what intellectual property attorneys should know about these issues and others outside their practice.

  8. March 21, 2023

    Amgen Must Face Regeneron's Bundling Antitrust Suit

    Amgen can't escape a lawsuit accusing it of using a bundling scheme to increase the sales of its cholesterol drug Repatha and push competitors out of the market, a Delaware federal judge has ruled.

  9. February 13, 2023

    Court Told Not To Toss Regeneron's Amgen Bundling Suit

    A magistrate judge recommended a Delaware federal court deny Amgen's attempts to toss or delay Regeneron's claims that Amgen Inc. used a bundling scheme to boost its cholesterol medication sales and said additional documents Amgen submitted should be ignored.

  10. August 09, 2022

    Amgen Looks To Duck Regeneron's Bundling Suit

    Pharmaceutical giant Amgen asked a Delaware federal court to throw out a suit from competitor Regeneron alleging that Amgen used a bundling scheme to boost its own cholesterol medication sales while ruining the market for Regeneron's competing product.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!